Alembic Pharmaceuticals has announced its consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported total income of ₹2,618.59 crore for the quarter and ₹4,783.29 crore for the half-year. Profit after tax for the quarter stood at ₹335.17 crore, with total comprehensive income at ₹328.86 crore.
Alembic Pharmaceuticals Reports Financial Results for Q2 FY27
Alembic Pharmaceuticals Limited has disclosed its consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results, which were subsequently reviewed by the statutory auditors.
Consolidated Financial Highlights
Quarter Ended September 30, 2026
For the quarter, the company recorded a Total Income of ₹2,618.59 crore. Total Expenses amounted to ₹2,179.27 crore. The Profit Before Exceptional Item and Tax was ₹437.95 crore. After accounting for tax expenses and non-controlling interests, the Profit for the Period after non-controlling interests stood at ₹335.17 crore. The Total Comprehensive Income for the period was ₹328.86 crore.
Half Year Ended September 30, 2026
For the six-month period, the Total Income reached ₹4,783.29 crore, with Total Expenses at ₹4,122.51 crore. The Profit Before Exceptional Item and Tax for the half-year was ₹659.81 crore. The Profit for the Period after non-controlling interests was reported as ₹508.23 crore, and the Total Comprehensive Income for the period was ₹503.50 crore.
Key Financial Metrics
The company’s financial statements also highlight various key ratios and metrics. For instance, the Debt-Equity Ratio was 0.25 for the quarter ended September 30, 2026. The Operating Margin stood at 22.21% for the quarter, and the Net Profit Margin was 12.87%.
Standalone Financials
The standalone results for the same period show a Total Income of ₹2,416.07 crore for the quarter and ₹4,298.17 crore for the half-year. Standalone profit after tax for the quarter was ₹409.36 crore, with total comprehensive income at ₹403.95 crore.
Source: BSE
